In vitro and in vivo biological evaluations indicated that [18F]1 possessed good stability, favorable pharmacokinetics and high signal-to-noise ratio in imaging the therapeutic efficacy of DOX on the cervical cancer, and the co-injection strategy of [18F]1 and 1 led to significantly increased tracer uptake in the tumor and remarkably enhanced signal-to-noise ratio, which correlated well with the expression level of active caspase-3 in drug-induced apoptotic tumor. The gene discussed is CASP3; the disease is neoplasm.